Evaluation of two molecular assays for rapid detection of Mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance settings

Journal of Clinical Microbiology

Volumn 49, Issue 8, 2011, Pages 2832-2837

  Kontsevaya, I ^a   Mironova, S ^a   Nikolayevskyy, V ^b   Balabanova, Y ^a,b   Mitchell, S ^b   Drobniewski, F ^b  

^a Samara Oblast Tuberculosis Dispensary   (Russian Federation)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CLUSTER ANALYSIS; CODON; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GYRA GENE; GYRB GENE; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; VARIABLE NUMBER OF TANDEM REPEAT;

ALLELES; AMINO ACID SUBSTITUTION; ANTITUBERCULAR AGENTS; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; RUSSIA; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79960961794     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01889-10     Document Type: Article

References (50)

1. Arnold, C. 2010. Rapid analysis of resistant mutant genotypes using pyrosequencing. Methods Mol. Biol. 642:217-223.
2. Atun, R. A., R. Lebcir, F. Drobniewski, and R. J. Coker. 2005. Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: system dynamics simulation model. Int. J. STD AIDS 16:560-570.
3. Aubry, A., et al. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104-112.
4. Bang, D., A. Bengard Andersen, and V. O. Thomsen. 2006. Rapid genotypic detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimens. J. Clin. Microbiol. 44:2605-2608.
5. Brossier, F., N. Veziris, A. Aubry, V. Jarlier, and W. Sougakoff. 2010. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 48:1683-1689.
6. Brown, T. J., L. Herrera-Leon, R. M. Anthony, and F. A. Drobniewski. 2006. The use of macroarrays for the identification of MDR Mycobacterium tuberculosis. J. Microbiol. Methods 65:294-300.
7. Drobniewski, F., et al. 2005. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 293:2726-2731. (Pubitemid 40965084)
8. Drobniewski, F. A., et al. 2005. Tuberculosis, HIV seroprevalence and intravenous drug abuse in prisoners. Eur. Respir. J. 26:298-304.
9. Duong, D. A., et al. 2009. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob. Agents Chemother. 53:4835-4839.
10. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. 2006. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 12:736-743.
11. Fang, R., et al. 2008. Mixed infections of Mycobacterium tuberculosis in tuberculosis patients in Shanghai, China. Tuberculosis (Edinb.) 88:469-473.
12. Gagneux, S., et al. 2006. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 103:2869-2873.
13. Gandhi, N. R., et al. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. (Pubitemid 44780738)
14. Ginsburg, A. S., J. H. Grosset, and W. R. Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432-442.
15. Halse, T. A., et al. 2010. Combined real-time PCR and rpoB gene pyrosequencing for rapid identification of Mycobacterium tuberculosis and determination of rifampin resistance directly in clinical specimens. J. Clin. Microbiol. 48:1182-1188.
16. Hillemann, D., S. Rusch-Gerdes, and E. Richter. 2007. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 45:2635-2640.
17. Hillemann, D., S. Rusch-Gerdes, and E. Richter. 2009. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 47:1767-1772.
18. Hofmann-Thiel, S., et al. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur. Respir. J. 33:368-374.
19. Jureen, P., et al. 2006. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by pyrosequencing technology. J. Clin. Microbiol. 44:1925-1929.
20. Kam, K. M., et al. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb. Drug Resist. 12:7-11.
21. Kamerbeek, J., et al. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35:907-914.
22. Kocagoz, T., et al. 1996. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 40:1768-1774.
23. Kruuner, A., M. D. Yates, and F. A. Drobniewski. 2006. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:811-818.
24. Ministry of Health of the Russian Federation. 2003. On improvement of TB control activities in the Russian Federation. Document 109. Ministry of Health of the Russian Federation, Moscow, Russian Federation.
25. Mokrousov, I., et al. 2002. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob. Agents Chemother. 46:1417-1424. (Pubitemid 34415323)
26. Mokrousov, I., et al. 2008. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob. Agents Chemother. 52:2937-2939.
27. Mokrousov, I., et al. 2003. PCR-based methodology for detecting multidrug-resistant strains of Mycobacterium tuberculosis Beijing family circulating in Russia. Eur. J. Clin. Microbiol. Infect. Dis. 22:342-348.
28. Mokrousov, I., T. Otten, B. Vyshnevskiy, and O. Narvskaya. 2002. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotypic resistance testing. J. Clin. Microbiol. 40:3810-3813.
29. Niemann, S., et al. 2009. Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. PLoS One 4:e7407.
30. Nikolayevsky, V., et al. 2004. Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation. J. Clin. Microbiol. 42:4498-4502.
31. Nikolayevskyy, V., et al. 2009. Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin. Pathol. 9:2.
32. Nikolayevskyy, V., et al. 2006. Differentiation of tuberculosis strains in a population with mainly Beijing-family strains. Emerg. Infect. Dis. 12:1406-1413.
33. Pfyffer, G. E., F. Palicova, and S. Rusch-Gerdes. 2002. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J. Clin. Microbiol. 40:1670-1674.
34. Piersimoni, C., A. Olivieri, L. Benacchio, and C. Scarparo. 2006. Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J. Clin. Microbiol. 44:20-28.
35. Pitaksajjakul, P., et al. 2005. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J. Trop. Med. Public Health 36(Suppl. 4):228-237.
36. Punga, V. V., et al. 2009. Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia. Int. J. Tuberc. Lung Dis. 13:1309-1312.
37. Rajasekaran, S., et al. 2009. HIV coinfection among multidrug resistant and extensively drug-resistant tuberculosis patients: a trend. J. Indian Med. Assoc. 107:281-286.
38. Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc. Lung Dis. 79:3-29.
39. Rinder, H., K. T. Mieskes, and T. Loscher. 2001. Heteroresistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 5:339-345.
40. Sreevatsan, S., et al. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl. Acad. Sci. U. S. A. 94:9869-9874.
41. Stavrum, R., et al. 2009. High diversity of Mycobacterium tuberculosis genotypes in South Africa and preponderance of mixed infections among ST53 isolates. J. Clin. Microbiol. 47:1848-1856.
42. Toungoussova, O. S., A. O. Mariandyshev, G. Bjune, D. A. Caugant, and P. Sandven. 2005. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur. J. Clin. Microbiol. Infect. Dis. 24:202-206.
43. Tungusova, O. S., A. O. Mar'iandyshev, H. Bewne, and P. Sandwen. 2004. Drug resistance of Mycobacterium tuberculosis of the genotype Beijing in imprisonment places in the Arkhangelsk Region. Probl. Tuberk. Bolezn. Legk. 2004:35-41. (In Russian.)
44. Velji, P., V. Nikolayevskyy, T. Brown, and F. Drobniewski. 2009. Discriminatory ability of hypervariable variable number tandem repeat loci in population-based analysis of Mycobacterium tuberculosis strains, London, UK. Emerg. Infect. Dis. 15:1609-1616.
45. Vitol, I., J. Driscoll, B. Kreiswirth, N. Kurepina, and K. P. Bennett. 2006. Identifying Mycobacterium tuberculosis complex strain families using spoligotypes. Infect. Genet. Evol. 6:491-504.
46. Von Groll, A., et al. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500.
47. Wang, J. C. 1985. DNA topoisomerases. Annu. Rev. Biochem. 54:665-697.
48. World Health Organization. 2008. Anti-tuberculosis drug resistance in the world, fourth global report. WHO/HTM/TB/2008.394. World Health Organization, Geneva, Switzerland.
49. World Health Organization. 2008. Molecular line probe assays for rapid screening of patients at risk of multidrug resistant tuberculosis (MDR-TB): policy statement. World Health Organization, Geneva, Switzerland.
50. Wright, A., et al. 2009. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373:1861-1873.